Last reviewed · How we verify
NCT04972097: PRESERVE
Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue
Completed
NA
Last updated 12 February 2025
What this trial tests
NA trial testing Irreversible Electroporation in Prostate Cancer in 121 participants. Completed in 14 August 2024.
Timeline
29 March 2022
Primary endpoint
14 August 2024
14 August 2024
14 August 2024
Quick facts
| Lead sponsor | Angiodynamics, Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 121 |
| Start date | 29 March 2022 |
| Primary completion | 14 August 2024 |
| Estimated completion | 14 August 2024 |
| Sites | 17 locations across United States |
Drugs / interventions tested
- Irreversible Electroporation
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
Angiodynamics, Inc.
Who can join
50 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pivotal study to evaluate the use of the NanoKnife System as a focal therapy option for prostate cancer patients. This study will assess the safety and effectiveness of the device when used to ablate prostate tissue in intermediate-risk prostate cancer patients.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Focal ablation therapy presents promising results for selectively localized prostate cancer patients.
Feng D, Li D, Xiao Y, Wu R, et al · · 2023 · cited 22× · PMID 37691892 · DOI 10.21147/j.issn.1000-9604.2023.04.08 -
A Description and Safety Overview of Irreversible Electroporation for Prostate Tissue Ablation in Intermediate-Risk Prostate Cancer Patients: Preliminary Results from the PRESERVE Trial.
George AK, Miocinovic R, Patel AR, Lomas DJ, et al · · 2024 · cited 8× · PMID 38927884 · DOI 10.3390/cancers16122178 -
Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial.
George AK, Miocinovic R, Patel AR, Lomas DJ, et al · · 2026 · cited 6× · PMID 40685282 · DOI 10.1016/j.eururo.2025.06.003 -
A narrative clinical trials review in the realm of focal therapy for localized prostate cancer.
Lazarovich A, Viswanath V, Dahmen AS, Sidana A. · · 2024 · cited 4× · PMID 39697719 · DOI 10.21037/tcr-23-2406 -
Revisiting Delphi to Create a Basis for the Future of Focal Therapy for Prostate Cancer.
Rodríguez-Sánchez L, Emberton M, de Reijke T, Stricker P, et al · · 2024 · cited 4× · PMID 37853538 · DOI 10.5534/wjmh.230160 -
Targeted microwave ablation of localised prostate cancer (VIOLETTE trial): a prospective multicentre study.
Delongchamps NB, Peltier A, Potiron E, Bladou F, et al · · 2026 · PMID 41810596 · DOI 10.1111/bju.70220 -
Pulsed electric fields: a sharp sword in the battle against cancers.
Zhang L, Dong S, Teng F, Wang Y, et al · · 2025 · PMID 41357174 · DOI 10.3389/fimmu.2025.1682539 -
A Description and Safety Overview of Irreversible Electroporation for Prostate Tissue Ablation in Intermediate-Risk Prostate Cancer Patients: Preliminary Results from the PRESERVE Trial
George A, Miocinovic R, Patel A, Lomas D, et al · · 2024
Verify or expand the search:
- PubMed search for NCT04972097
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Irreversible Electroporation
Trials testing the same drug.
- NCT06378047 — Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer · Phase 1 · completed
- NCT03257150 — A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer · NA · completed
- NCT03080974 — Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT03008343 — Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer · Phase 1, PHASE2 · completed
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Angiodynamics, Inc. trials
Trials by the same sponsor.
- NCT05318092 — Evaluating the Safety and Efficacy of the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE for Treatment of Ac · NA · completed
- NCT04229563 — Post-Market Registry of AURYON™ Atherectomy Device in Subjects Affected With Infrainguinal Peripheral Artery Disease · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04972097 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Angiodynamics, Inc.
- Last refreshed: 12 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04972097.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing